Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Hudbay Minerals Inc. Ordinary Shares (Canada) (HBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Hudbay Minerals Inc. Ordinary Shares (Canada) — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while Hudbay Minerals Inc. Ordinary Shares (Canada) trades at $23.89 (market cap $11.37B). The key difference: Hudbay Minerals Inc. Ordinary Shares (Canada) is far larger — about 4× Dyne Therapeutics Inc. Common Stock's market cap, and Hudbay Minerals Inc. Ordinary Shares (Canada) pays a 0.11% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Hudbay Minerals Inc. Ordinary Shares (Canada) for 6 Days on average.
| DYN | HBM | |
|---|---|---|
Market Cap | $2.86B | $11.37B |
Volume | 3,341,579 | 3,520,423 |
Sector | Health | Basic Materials |
52-Week High | $26.78 | $31.87 |
52-Week Low | $14.60 | $14.58 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.18B | $11.43B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
HudBay Minerals (HBM) trades at $25.68, down 0.31% with bearish technical signals despite solid fundamentals. The company reported strong 2025 results with $2.21B revenue and $568.5M net income, while analyst consensus remains positive with 60% buy ratings. Recent news highlights HBM4 equipment delays and copper/gold reserve expansions at Snow Lake operations.
HBM presents a value opportunity with reasonable valuation (P/E 15.77) and strong profitability (ROE 18.43%), though technical weakness and HBM market dynamics pose near-term risks. The stock's outlook depends on execution of copper growth strategy and resolution of memory sector supply chain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Hudbay Minerals Inc. Ordinary Shares (Canada)
Hudbay Minerals is a mining company producing copper, gold, zinc, and other metals. Its operations are located in the Americas.
Read more on HBM →
